



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/805,664	03/13/2001	Judith W. Zyskind	07252-008002	3663

7590 08/07/2002  
GREGORY P. EINHORN  
Fish & Richardson P.C.  
4350 La Jolla Village Drive, Suite 500  
San Diego, CA 92122

EXAMINER

FREDMAN, JEFFREY NORMAN

ART UNIT	PAPER NUMBER
----------	--------------

1637

DATE MAILED: 08/07/2002

13

Please find below and/or attached an Office communication concerning this application or proceeding.

# Office Action Summary

Application No.

09/805,664

Applicant(s)

ZYSKIND ET AL.

Examiner

Jeffrey Fredman

Art Unit

1637

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

## Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

## Status

- 1) ☐ Responsive to communication(s) filed on 01 July 2002.
- 2a) ☐ This action is **FINAL**.
- 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

## Disposition of Claims

- 4) ☒ Claim(s) 1-88 is/are pending in the application.
- 4a) Of the above claim(s) 6,7,38-43,51-53,56,81,82 and 88 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-5,8-37,44-50,54,55,57-80 and 83-87 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

## Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on \_\_\_\_\_ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

## Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

## Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449) Paper No(s) 5, 6.

- 4) ☐ Interview Summary (PTO-413) Paper No(s). \_\_\_\_\_.
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: \_\_\_\_\_.

**DETAILED ACTION**

***Election/Restrictions***

1. Applicant's election without traverse of Group II, species *E. coli* Via gene and bacterium in Paper No. 12 is acknowledged. Claims 6, 7, 38-43, 51-53, 56, 81, 82, 88 are drawn to non elected species or groups.

***Priority***

2. Applicant has not complied with one or more conditions for receiving the benefit of an earlier filing date under 35 U.S.C. 120 as follows:

An application in which the benefits of an earlier application are desired must contain a specific reference to the prior application(s) in the first sentence of the specification or in an application data sheet (37 CFR 1.78(a)(2) and (a)(5)).

***Claim Rejections - 35 USC § 103***

3. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

4. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to

Art Unit: 1637

consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

5. Claims 1-5, 8-22, 24, 26-30, 32, 34-36, 44-50, 54, 55, 57, 58, 61, 63-71, 75, 77-80 and 83-87, are rejected under 35 U.S.C. 103(a) as being unpatentable over Benton et al (U.S. Patent 6,037,123) in view of Kamb et al (U.S. Patent 5,955,276) and further in view of Timberlake et al (U.S. Patent 5,821,076).

Benton teaches a method of screening for an antimicrobial agent (see column 9, line 39 and abstract), comprising the steps:

(a) providing a test compound, an essential gene for proliferation and two samples of a microorganism (see column 255, lines 1-52 and column 9, lines 9-64), (here, for example, the test compounds are the compounds of figure 19, the proliferation gene is the endogenous bacterial proliferation gene NT94 and the two cells are cells with temperature sensitive NT94 and extra wild type copies of NT94)

(b) introducing the microbial proliferation gene into the microorganisms of the first sample (see column 255, lines 1-52) (As noted above, this step is met by the introduction of the wildtype NT94 into the microorganism in the sense orientation)

(c) contacting the test compound with the first sample and second microorganism samples which are viable cells (see column 255, lines 1-52) (The contacting of at least the four compounds of figure 19 is demonstrated),

(d) determining the effect of the test compound on the first and second microorganism samples wherein the test compound is identified as an antimicrobial agent based upon the effect on the gene product where if there is a difference in effect, the compound is identified as antimicrobial (see column 255, lines 1-52 and column 9, lines 9-64)( here a significant inhibition is shown).

Benton further teaches that one effect which can be measured is whether the compound is bacteriostatic and impedes proliferation or is bacteriocidal and kills the cells (also impeding proliferation, necessarily) (column 241, lines 30-67) as well as changes in transcription, metabolism and consequent protein synthesis and rates of translation (column 241, lines 30-67).

Benton teaches analysis of the effect on the polypeptide by immunoassays, enzymatic activity assays which may be direct or indirect (see column 257, lines 42-53).

Benton teaches the use of regulatable promoters (column 241, lines 5-11) including temperature sensitive promoters (column 245).

Benton teaches screening Staph. Aureus, a bacterium which is a gram positive pathogenic bacterium (columns 239-240 and column 255, line 12) as well as Salmonella typhimurium, a gram negative bacterium (column 246, line 21) and Escherichia coli (column 139, line 47).

Benton teaches the use of NT94, which is an exogenous nucleic acid in a plasmid vector that is 925 nucleotides in length and is derived from genomic DNA (see column 139 and 140).

Benton teaches a library of four compounds which compounds are organic (see figure 19) as well as combinatorial libraries (see column 259, line 13).

Benton teaches replica plating (column 249, lines 55-67).

Benton teaches measurement of colony forming units (column 244, lines 1-4).

Benton does not teach a method for identification of microbial proliferation genes by using random fragments.

Kamb teaches a method for identification of genes comprising the steps of: a) introducing an exogenous nucleic acid into a microorganism operably linked to a promoter element which is effective for controlling expression in the sense orientation having substantial sequence identity to an endogenous gene of the microorganism (column 19, lines 5-54), b) determination of the effect of the introduced sense nucleic acid upon the microorganism compared to the microorganism without the introduced antisense nucleic acid (column 19, lines 55 to column 20, line 14). Kamb further teaches that the screen may be for dominant negative proteins which interfere with normal function (column 19, line 66 to column 20, line 14). Kamb further teaches the use of fluorescent labels as a marker for expression (column 20, lines 15-22). Kamb teaches nucleic acids in the range of 15 to 1500 nucleotides in length including the use of random DNA fragments derived from either sheared or digested DNA (column 11, lines 44-54). Kamb teaches a range of possible organisms (claims 11-16 and column

Art Unit: 1637

2). Kamb teaches screening small molecules, which include inorganic compounds (see column 17, lines 55-67).

Kamb further teaches performance of the assay in vitro, such as cell lysates (see column 18, lines 4-12).

Timberlake evidences that essential genes are required for proliferation, stating, "Essential survival genes are required for growth (e.g., metabolism, division, or reproduction). Such genes and gene products are useful in developing therapeutic agents such as antifungal, antibacterial, and antiparasitic agents; insecticidal agents; and preventative antimicrobial agents. Therapeutic agents can reduce or prevent growth, or decrease pathogenicity or virulence, and preferably, kill the organism. The genes and gene products identified by the invention can also be used to develop antimicrobial agents which are effective in preventing microbial infection, e.g., by inhibiting the establishment of a bacterial biofilm, in addition to agents which are useful in the treatment of an established infection (column 2, lines 7-19)".

It would have been *prima facie* obvious to one having ordinary skill in the art at the time the invention was made to combine the gene identification method of Kamb with the antimicrobial screening method of Benton since Benton states "Thus, the invention provides a method of screening for an antibacterial agent by determining the effects of a test compound on the amount or level of activity of a polypeptide gene product of one of the identified essential genes (column 9, lines 22-26)". The ordinary artisan would identify these essential genes using the method of Kamb since Kamb

states "The present invention is directed to a method of genetic analysis that satisfies the need for a simple, rapid, and general way to identify components of genetic pathways that regulate traits of interest.(column 3, lines 1-5)". Thus, an ordinary practitioner would have been motivated to use the method of Kamb to identify the essential genes used by Benton in order to use a simple, rapid and general method to identify traits of interest.

6. Claims 23, 31, 59 and 60 are rejected under 35 U.S.C. 103(a) as being unpatentable over Benton et al (U.S. Patent 6,037,123) in view of Kamb et al (U.S. Patent 5,955,276) and further in view of Timberlake et al (U.S. Patent 5,821,076) and further in view of Gossen et al (Current Opinion Biotechnology (1994) 5:516-520).

Benton in view of Kamb and further in view of Timberlake teach the method of claims 1-5, 8-22, 24, 26-30, 32, 34-36, 44-50, 54, 55, 57, 58, 61, 63-71, 75, 77-80 and 83-87 as discussed above.

Benton in view of Kamb and further in view of Timberlake does not teach the use of all different sorts of inducible promoters.

Gossen teaches the use of inducible promoters under control of outside stimulants (page 516, column 2 to page 517, column 1).

It would have been *prima facie* obvious to one having ordinary skill in the art at the time the invention was made to combine the gene identification method of Benton in view of Kamb and further in view of Timberlake with the use of inducible promoters as taught by Gossen since Gossen states "An essential feature of such regulatory systems is the potential to control the activity of a gene in a reversible and temporally



defined manner. This will open up new approaches for the analysis of differentiation and developmental processes (page 516, column 1)". An ordinary practitioner would have been motivated to utilize the inducible promoters of Gossen in the gene identification method of Benton in view of Kamb and further in view of Timberlake in order to permit controlled activation of the protein in order to maximize specific effects and minimize non-specific effects of the protein in the analysis of the developmental process of the microbial cells.

7. Claims 25, 33 and 62 are rejected under 35 U.S.C. 103(a) as being unpatentable over Benton et al (U.S. Patent 6,037,123) in view of Kamb et al (U.S. Patent 5,955,276) and further in view of Timberlake et al (U.S. Patent 5,821,076) and further in view of Mirabelli et al (U.S. Patent 5,639,595).

Benton in view of Kamb and further in view of Timberlake teach the method of claims 1-5, 8-22, 24, 26-30, 32, 34-36, 44-50, 54, 55, 57, 58, 61, 63-71, 75, 77-80 and 83-87 as discussed above.

Benton in view of Kamb and further in view of Timberlake does not teach the use of antisense components in the screening.

Mirabelli teaches screening randomly sheared antisense to identify new drugs and reagents for treatment (see column 6, lines 25-50 and column 8, lines 4-5).

It would have been *prima facie* obvious to one having ordinary skill in the art at the time the invention was made to combine the gene identification method of Benton in view of Kamb and further in view of Timberlake with the use of antisense oriented genes since Mirabelli states "The cDNA can then be directionally cloned into the

Art Unit: 1637

expression vector such that RNAs are produced in an antisense orientation. This approach can identify new genes that are key to successful infection. (column 8, lines 3-6)". An ordinary practitioner would have been motivated to place genes into the antisense orientation to identify essential genes, a desired element of each of Benton, Kamb and Timberlake.

8. Claims 72-74 are rejected under 35 U.S.C. 103(a) as being unpatentable over Benton et al (U.S. Patent 6,037,123) in view of Kamb et al (U.S. Patent 5,955,276) and further in view of Timberlake et al (U.S. Patent 5,821,076) and further in view of Lam et al (U.S. Patent 5,510,240).

Benton in view of Kamb and further in view of Timberlake teach the method of claims 1-5, 8-22, 24, 26-30, 32, 34-36, 44-50, 54, 55, 57, 58, 61, 63-71, 75, 77-80 and 83-87 as discussed above.

Benton in view of Kamb and further in view of Timberlake does not teach test compounds which are inorganic, peptidomimetics, peptides or oligonucleotides.

Lam teaches screening compounds including peptidomimetics, oligonucleotides and peptides (column 6, lines 57-67).

It would have been *prima facie* obvious to one having ordinary skill in the art at the time the invention was made to combine the library of Lam with the screening method of Benton in view of Kamb and further in view of Timberlake since Lam states "Thus, there is a need in the art for a library of truly random peptide sequences, and oligonucleotide sequences, i.e., bio-oligomer sequences in which a single bio-oligomer species can be readily and quickly isolated from the rest of the library. There is also a

need in the art for a method for quickly and inexpensively synthesizing thousands to millions of these truly random bio-oligomer sequences. (column 4, lines 51-57)". ). An ordinary practitioner would have been motivated to utilize the library components of Lam in the gene identification method of Benton in view of Kamb and further in view of Timberlake in order to quickly and inexpensively screen species which are readily isolated from the library and which may have the desired antimicrobial effect.

9. Claims 76 is rejected under 35 U.S.C. 103(a) as being unpatentable over Benton et al (U.S. Patent 6,037,123) in view of Kamb et al (U.S. Patent 5,955,276) and further in view of Timberlake et al (U.S. Patent 5,821,076) and further in view of Matsunaga et al (U.S. Patent 4,788,038).

Benton in view of Kamb and further in view of Timberlake teach the method of claims 1-5, 8-22, 24, 26-30, 32, 34-36, 44-50, 54, 55, 57, 58, 61, 63-71, 75, 77-80 and 83-87 as discussed above.

Benton in view of Kamb and further in view of Timberlake does not teach measurement of respiratory activity for cell viability.

It would have been *prima facie* obvious to one having ordinary skill in the art at the time the invention was made to combine the respiratory activity measurement of Matsunaga with the screening method of Benton in view of Kamb and further in view of Timberlake since Matsunaga notes that "The process enables cellular activities such as respiratory activity to be selectively and effectively inhibited and controlled (column 1, lines 32-34). An ordinary practitioner would have recognized that respiratory activity

of a cell is an equivalent mechanism for measurement of cell viability to counting colonies since Matsunaga shows that this measures cell viability.

***Double Patenting***


10. It is noted that there is a related patent, U.S. 6,228,579, but the claims of this patent are drawn to a different restriction group. Consequently, double patenting is not permitted in this situation according to MPEP 804.01.

***Conclusion***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jeffrey Fredman whose telephone number is 703-308-6568. The examiner can normally be reached on 6:30-4:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on 703-308-1119. The fax phone numbers for the organization where this application or proceeding is assigned are 703-305-3014 for regular communications and 703-305-3014 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

  
Jeffrey Fredman  
Primary Examiner  
Art Unit 1637

July 30, 2002